ZURICH, Oct 18 (Reuters) - Novartis AG reported a bigger than expected fall in its third-quarter net profit on Thursday after a one-off charge and as rivals launched cheaper versions of its drugs, but markets welcomed a revamp of its U.S. drugs business.
